tiprankstipranks
Trending News
More News >
Crescent Biopharma, Inc. (CBIO)
:CBIO
Advertisement

Crescent Biopharma (CBIO) AI Stock Analysis

Compare
988 Followers

Top Page

No summary available
Positive Factors
Negative Factors

Crescent Biopharma (CBIO) vs. SPDR S&P 500 ETF (SPY)

Crescent Biopharma Business Overview & Revenue Model

Company DescriptionCrescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
How the Company Makes MoneyGlycoMimetics generates revenue primarily through research and development collaborations, milestone payments, and licensing agreements with larger pharmaceutical companies. These partnerships provide funding and resources for the development of its drug candidates. The company may also receive royalties from the commercial sales of any successfully developed products. As GlycoMimetics is a clinical-stage company, it does not yet have products on the market and thus does not generate revenue from direct product sales. Instead, its financial performance depends heavily on its ability to secure and maintain strategic partnerships to advance its drug pipeline toward commercialization.

Crescent Biopharma Earnings Call Summary

Earnings Call Date:May 01, 2025
(Q1-2024)
|
% Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The earnings call revealed challenges with the Phase III trial not meeting its primary endpoint, leading to financial and strategic reassessments. However, there is a commitment to further analyze the rich data collected and ongoing trials continue to explore the potential of uproleselan in AML treatment.
Q1-2024 Updates
Positive Updates
Low Discontinuation Rate
The study had a low discontinuation rate of 3%, indicating good patient retention and adherence to the trial protocol.
Rich Data Set for Future Analysis
The study involved 388 patients with an unprecedented follow-up of over 3 years, providing a rich data set for further analysis and potential insights into AML treatment.
Commitment to Further Research
Despite the trial's primary endpoint not being met, GlycoMimetics remains committed to exploring uproleselan's potential in AML and plans to conduct a rigorous analysis of the data.
Ongoing Trials and Future Plans
The National Cancer Institute is sponsoring an ongoing Phase II/III trial evaluating uproleselan in newly diagnosed older patients with AML, and results will be shared when available.
Negative Updates
Phase III Study Did Not Meet Primary Endpoint
The pivotal Phase III study of uproleselan did not achieve a statistically significant improvement in overall survival in the intent-to-treat population.
Unprecedented Control Group Survival
The control group showed a median overall survival of 12.3 months, which is unprecedented in relapsed/refractory AML trials, potentially affecting the study's outcomes.
Financial and Budgetary Concerns
The company is evaluating ways to reduce cash burn and is expected to report back to investors with a revised budget.
Company Guidance
During the Q1 2024 earnings call for GlycoMimetics, the management provided updates on the Phase III study of their lead drug candidate, uproleselan, which unfortunately did not achieve a statistically significant improvement in overall survival for patients with relapsed/refractory acute myeloid leukemia (AML). The trial involved 388 patients across 70 sites in 9 countries, with a median overall survival of 13 months for the uproleselan arm and 12.3 months for the placebo arm. Despite not meeting its primary endpoint, the study's unexpected control group survival rate of over one year is considered unprecedented in this setting. The company plans to conduct a comprehensive analysis of the data in collaboration with medical, statistical, and regulatory experts and intends to present findings at a future medical meeting. Additionally, GlycoMimetics highlighted ongoing studies, including a National Cancer Institute-sponsored Phase II/III trial, and mentioned efforts to manage cash burn and revise budget plans as they proceed with further analyses and discussions with the FDA.

Crescent Biopharma Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
BreakdownTTMDec 2024Dec 2022Dec 2021Dec 2020Dec 2019
Income Statement
Total Revenue0.000.0075.00K1.16M10.16M0.00
Gross Profit0.00-35.17K75.00K1.16M0.00-899.30K
EBITDA-34.14M-37.84M-47.20M-63.18M-51.24M-56.99M
Net Income-41.18M-37.88M-46.69M-63.43M-51.03M-54.12M
Balance Sheet
Total Assets157.43M35.62M51.81M94.35M142.83M167.97M
Cash, Cash Equivalents and Short-Term Investments152.65M34.77M47.87M90.25M137.03M158.20M
Total Debt1.64M37.48M918.55K1.92M2.82M3.62M
Total Liabilities18.18M47.10M8.88M12.74M14.61M13.77M
Stockholders Equity139.25M-11.48M42.93M81.60M128.22M154.20M
Cash Flow
Free Cash Flow-27.42B-31.11M-46.54M-57.50M-39.31M-52.13M
Operating Cash Flow-27.41B-31.10M-46.46M-57.49M-39.24M-51.98M
Investing Cash Flow-10.07M20.03K-84.19K-14.94K-68.51K-144.93K
Financing Cash Flow150.77M5.40K4.16M10.72M18.14M412.91K

Crescent Biopharma Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price12.54
Price Trends
50DMA
12.83
Negative
100DMA
14.15
Negative
200DMA
19.77
Negative
Market Momentum
MACD
-0.44
Negative
RSI
52.25
Neutral
STOCH
55.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBIO, the sentiment is Neutral. The current price of 12.54 is above the 20-day moving average (MA) of 11.97, below the 50-day MA of 12.83, and below the 200-day MA of 19.77, indicating a neutral trend. The MACD of -0.44 indicates Negative momentum. The RSI at 52.25 is Neutral, neither overbought nor oversold. The STOCH value of 55.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CBIO.

Crescent Biopharma Risk Analysis

Crescent Biopharma disclosed 59 risk factors in its most recent earnings report. Crescent Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Crescent Biopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
44
Neutral
$25.11M-112.22%
43
Neutral
$6.94M-12.98%-0.97%64.07%
39
Underperform
$12.76M-26.83%65.38%
38
Underperform
$13.94M-101.64%81.20%
28
Underperform
$20.99M-150.58%99.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CBIO
Crescent Biopharma
12.35
-3.49
-22.03%
XTLB
XTL Biopharmaceuticals Sponsored ADR
1.26
-0.83
-39.71%
AKTX
Akari Therapeutics
0.80
-1.44
-64.29%
BIVI
BioVie
1.91
-21.59
-91.87%
CAPS
Capstone Therapeutics
1.02
-2.08
-67.10%
ALLR
Allarity Therapeutics
1.44
-0.29
-16.76%

Crescent Biopharma Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
GlycoMimetics Faces Leadership Changes Amid Board Resignations
Negative
Feb 25, 2025

On February 19, 2025, GlycoMimetics received a termination notice from Apollomics, ending their Collaboration and License Agreement effective January 2, 2020, which granted Apollomics rights to develop and commercialize uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau, and Taiwan. This termination, effective 90 days post-notice, relieves GlycoMimetics of any material obligations under the agreement. Additionally, on February 21, 2025, several directors, including the CEO and CFO, resigned from GlycoMimetics’ Board, with the CEO and CFO entering into separation and consulting agreements. These changes indicate a significant shift in the company’s leadership structure.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―